| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8242294 | ABBVIE | Synthetic bile acid compositions and methods |
May, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846066 | ABBVIE | Methods and related compositions for reduction of fat and skin tightening |
Feb, 2025
(9 months from now) | |
| US8298556 | ABBVIE | Methods and related compositions for the non-surgical removal of fat |
Aug, 2025
(1 year, 2 months from now) | |
| US7622130 | ABBVIE | Methods and compositions for the non-surgical removal of fat |
Dec, 2027
(3 years from now) | |
| US7754230 | ABBVIE | Methods and related compositions for reduction of fat |
Dec, 2027
(3 years from now) | |
| US8461140 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US8546367 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US9949986 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US9636349 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US9522155 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US8883770 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US8367649 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
| US8101593 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
| US10500214 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
| US8653058 | ABBVIE | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
Mar, 2030
(5 years from now) | |
Kybella is owned by Abbvie.
Kybella contains Deoxycholic Acid.
Kybella has a total of 15 drug patents out of which 0 drug patents have expired.
Kybella was authorised for market use on 29 April, 2015.
Kybella is available in solution;subcutaneous dosage forms.
Kybella can be used as improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as described in the approved labeling, method for reduction of submental fat.
The generics of Kybella are possible to be released after 02 March, 2030.
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: Method for reduction of submental fat; Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as de...
Dosage: SOLUTION;SUBCUTANEOUS
KYBELLA family patents
